GRI Bio Inc
gribio.comWhat Do They Do?
Develops experimental medicines for patients with fibrotic lung, inflammatory and autoimmune diseases, including idiopathic pulmonary fibrosis and lupus.
10-K for FY2025, filed Jan 30, 2026We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target…View ↗
Our product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells. The active pharmaceutical…View ↗
Our product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$1.6MView ↗
- ▼ −43% (Loss)
- vs −$2.9M in Q2 FY2025
Portfolio focus
The older report centered on abuse-deterrent medicines for nervous system disorders, including attention-deficit hyperactivity disorder and narcolepsy. The latest centers on therapies for inflammatory, fibrotic and autoimmune diseases.
10-K for FY2022, filed Feb 24, 2023 10-K for FY2025, filed Jan 30, 2026Historically, we have been primarily focused on the development and commercialization of novel abuse-deterrent medications for CNS…View ↗
We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target…View ↗
Commercial rights
The older report described an exclusive European license to Medice for an abuse-deterrent medicine, with upfront, milestone and sales-based royalty payments. The latest says the company retains global rights to its candidates and plans to commercialize approved products itself or with partners.
10-K for FY2022, filed Feb 24, 2023 10-K for FY2025, filed Jan 30, 2026In January 2020, we entered into a license agreement with Medice (Medice License Agreement), which grants Medice an exclusive license to…View ↗
Who Do They Compete With?
Competes with AbbVie, AstraZeneca, Avalyn Pharma, Boehringer Ingelheim International, Bristol-Myers Squibb, Contineum Therapeutics, Daewoong Pharmaceutical, Eli Lilly and, Endeavor Biomedicines, Genentech, GlaxoSmithKline, Guangzhou JOYO Pharma, InSilico Medicine Hong Kong, Mediar Therapeutics, PureTech Health, Redx Pharma, Rein Therapeutics, Sunshine Lake Pharma, Suzhou Zelgen Biopharmaceuticals, and United Therapeutics
10-K for FY2025, filed Jan 30, 2026IPF - AbbVie Inc., AstraZeneca PLC, Avalyn Pharma Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Contineum…View ↗
Loading...
